.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,348,216

« Back to Dashboard

Claims for Patent: 6,348,216

Title: Ibuprofen and narcotic analgesic compositions
Abstract:Provided herein are compositions and methods of making compositions of ibuprofen in combination with a narcotic analgesic. Specifically provided is a pharmaceutical tablet composition comprising ibuprofen; a narcotic analgesic; colloidal silicon dioxide; a filler selected from the group consisting of microcrystalline cellulose and powdered cellulose; a disintegrant selected from the group consisting of croscarmellose sodium, crospovidone, and sodium starch glycolate; a binder consisting of an akylhydroxy methylcellulose; a starch; and a lubricant. Also provided herein is a method of preparing a pharmaceutical tablet composition comprising: (a) Granulating ibuprofen, a narcotic analgesic, a first glidant, a first disintegrant, a binder, and starch to form granules wherein said granulating step comprises a wet granulation process; (b) blending the granules with extra-granular material comprised of a second glidant, a second disintegrant, a filler and starch to form a blend of granules and extra-granular material; and (c) compressing the blend into a tablet.
Inventor(s): Kushla; Gregory P. (Florham Park, NJ), Lai; Jin-Wang (Edison, NJ), Polli; Gerald P. (Valley Forge, PA)
Assignee: Knoll Pharmaceutical Company (Mt. Olive, NJ)
Application Number:08/872,216
Patent Claims: 1. A pharmaceutical tablet comprising a compressed composition substantially free of lactose and polyvinylpyrrolidone, said compressed composition comprising a granule comprised of:

a) ibuprofen;

b) hydrocodone bitartrate;

c) colloidal silicon dioxide;

d) a filler selected from the group consisting of microcrystalline cellulose and powdered cellulose;

e) a disintegrant; and a

f) starch;

wherein the granule is formed by a wet granulation process and said granule comprises the ibuprofen and the hydrocodone bitartrate in a single phase; and wherein the composition further comprises an extra granule material comprising a lubricant; and wherein the composition flows well, has good compression performance and can be compressed over a wider range of compression forces with no substantial change in the disintegration time of the tablet; and wherein said ibuprofen, said hydrocodone bitartrate, and said lubricant are present in said tablet in a single phase.

2. A pharmaceutical tablet composition comprising a tablet material comprised of:

a) about 25% to about 63%, by total weight of the tablet, of ibuprofen;

b) about 0.6% to about 3.8%, by weight, of hydrocodone bitartrate;

c) colloidal silicon dioxide wherein the weight of the colloidal silicon dioxide is provided in a range, of the total weight of the tablet, of about 0.5% to about 3%;

d) a filler selected from the group consisting of microcrystalline cellulose and powdered cellulose, wherein the weight of the filler is provided in a range, of the total weight of the tablet, of about 10% to about 42%;

e) a disintegrant selected from the group consisting of croscarmellose sodium, crospovidone, and sodium starch glycolate wherein the weight of the disintegrant is provided in a range, of the total weight of the tablet, of about 4% to about 10%;

f) a binder comprising an alkylhydroxy methylcellulose wherein the weight of the binder is provided in a range, of the total weight of the tablet composition, of about 2% to less than 6%;

g) a starch provided in a weight range, of the total weight of the tablet composition, of about 11% to about 20%; and

h) a lubricant wherein the lubricant is provided in an amount less than 1% by weight of the total weight of the tablet;

and wherein the tablet comprises a compressed blend of a granule and extra granule material and wherein the granule comprises granulate material comprised of:

1) the ibuprofen;

2) the hydrocodone bitartrate;

3) about 0.5% to about 2.0%, of the total weight of the tablet composition, of colloidal silicon dioxide;

4) about 9.5% to about 22%, of the total weight of the tablet composition, of filler;

5) about 4%, of the total weight of the tablet composition, of disintegrant;

6) about 6% to about 12%, of the total weight of the tablet composition of starch;

wherein the extra granule material comprises the remaining amount of the tablet material; the composition is substantially free of lactose and polyvinylpyrrolidone and wherein the composition flows well, has good compression performance and can be compressed over a wide range of compression forces with no substantial change in the disintegration time of the tablet.

3. The composition as recited in claim 2 wherein the weight of the filler is provided in range, of the total weight of the tablet composition, of about 15% to about 25%.

4. The composition as recited in claim 2 wherein the weight of the disintegrant is provided in a range of about 6% to about 8%.

5. The composition as recited in claim 3 wherein the weight of the disintegrant is provided in a range of about 6% to about 8%.

6. The composition as recited in claim 2 wherein the weight of the colloidal silicon dioxide is in a range of the total weight of the tablet, of about 1.5% to about 2%.

7. The composition as recited in claim 3 wherein the weight of the colloidal silicon dioxide is in a range, of the total weight of the tablet, of about 1.5% to about 2%.

8. The composition as recited in claim 4 wherein the weight of the colloidal silicon dioxide is in a range, of the total weight of the tablet, of about 1.5% to about 2%.

9. The composition as recited in claim 5 wherein the weight of the colloidal silicon dioxide is in a range, of the total weight of the tablet, of about 1.5% to about 2%.

10. The composition as recited in claim 2 wherein the weight of the binder is in a range, of the total weight of the tablet, of about 3% to about 4%.

11. The composition as recited in claim 3 wherein the weight of the binder is in a range, of the total weight of the tablet, of about 3% to about 4%.

12. The composition as recited in claim 4 wherein the weight of the binder is in a range, of the total weight of the tablet, of about 3% to about 4%.

13. The composition as recited in claim 5 wherein the weight of the binder is in a range, of the total weight of the tablet, of about 3% to about 4%.

14. The composition as recited in claim 6 wherein the weight of the binder is in a range, of the total weight of the tablet, of about 3% to about 4%.

15. The composition as recited in claim 7 wherein the weight of the binder is in a range, of the total weight of the tablet, of about 3% to about 4%.

16. The composition as recited in claim 8 wherein the weight of the binder is in a range, of the total weight of the tablet, of about 3% to about 4%.

17. The composition as recited in claim 9 wherein the weight of the binder is in a range, of the total weight of the tablet, of about 3% to about 4%.

18. The composition as recited in claim 2 wherein the weight of the starch is in a range, of the total weight of the tablet, of about 6% to about 8%.

19. The composition as recited in claim 3 wherein the weight of the starch is in a range, of the total weight of the tablet, of about 6% to about 8%.

20. The composition as recited in claim 4 wherein the weight of the starch is in a range, of the total weight of the tablet, of about 6% to about 8%.

21. The composition as recited in claim 5 wherein the weight of the starch is in a range, of the total weight of the tablet, of about 6% to about 8%.

22. The composition as recited in claim 6 wherein the weight of the starch is in a range, of the total weight of the tablet, of about 6% to about 8%.

23. The composition as recited in claim 7 wherein the weight of the starch is in a range, of the total weight of the tablet, of about 6% to about 8%.

24. The composition as recited in claim 8 wherein the weight of the starch is in a range, of the total weight of the tablet, of about 6% to about 8%.

25. The composition as recited in claim 9 wherein the weight of the starch is in a range, of the total weight of the tablet, of about 6% to about 8%.

26. The composition as recited in claim 10 wherein the weight of the starch is in a range, of the total weight of the tablet, of about 6% to about 8%.

27. The composition as recited in claim 11 wherein the weight of the starch is in a range, of the total weight of the tablet, of about 6% to about 8%.

28. The composition as recited in claim 12 wherein the weight of the starch is in a range, of the total weight of the tablet, of about 6% to about 8%.

29. The composition as recited in claim 13 wherein the weight of the starch is in a range, of the total weight of the tablet, of about 6% to about 8%.

30. The composition as recited in claim 14 wherein the weight of the starch is in a range, of the total weight of the tablet, of about 6% to about 8%.

31. The composition as recited in claim 15 wherein the weight of the starch is in a range, of the total weight of the tablet, of about 6% to about 8%.

32. The composition as recited in claim 16 wherein the weight of the starch is in a range, of the total weight of the tablet, of about 6% to about 8%.

33. The composition as recited in claim 17 wherein the weight of the starch is in a range, of the total weight of the tablet, of about 6% to about 8%.

34. A pharmaceutical composition comprising tablet material comprised of:

a) about 50% ibuprofen;

b) about 1.88% hydrocodone bitartrate;

c) about 1.5% colloidal silicon dioxide;

d) about 19.3% microcrystalline cellulose as the filler;

e) about 8% sodium croscarmellose as the disintegrant;

f) about 3.25% hydroxypropyl methylcellulose as the binder;

g) about 15.6% corn starch as the starch;

h) about 0.5% magnesium stearate, wherein the total percent of the tablet material is equal to about 100% of the weight of the tablet; wherein the tablet comprises a compressed blend of a granule and extra granulate material wherein the granule comprises as a portion of the tablet material that comprises the total weight of the tablet as follows:

a) about 50% ibuprofen;

b) about 1.9% hydrocodone bitartrate;

c) about 0.75% colloidal silicon dioxide;

d) about 9.5% microcrystalline cellulose;

e) about 4.0% croscarmellose sodium;

f) about 10.6% corn starch; and

g) about 3.3% hydroxypropyl methylcellulose; and the extra granule material comprises the remaining amount of tablet material and the composition is substantially free of lactose and polyvinylpyrrolidone.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc